Source - SMW
Imperial Innovations Group has noted that portfolio company TopiVert Pharma Ltd has today announced that the first patients have been dosed in a phase IIa proof-of-concept study to evaluate the safety/tolerability and efficacy of a rectal formulation of TOP1288 in symptomatic ulcerative colitis patients with moderate to severe disease activity.

TOP1288, a potent inhibitor of key kinases involved in inflammation, is being developed by TopiVert as a topical therapy for UC, a form of inflammatory bowel disease (IBD) which affects the colon.

Related Charts

Imperial Innovations Group (IVO)

-20.75p (-5.31%)
delayed 18:15PM